Trapidil
Chemical compound
From Wikipedia, the free encyclopedia
Trapidil is used in the treatment of chronic stable angina pectoris. It is currently marketed in Japan under the brand name Rocornal.[1]
| |
| Clinical data | |
|---|---|
| Trade names | Rocornal, Avantrin, Travisco |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.035.834 |
| Chemical and physical data | |
| Formula | C10H15N5 |
| Molar mass | 205.265 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Pharmacology
Based on cell free in vitro activity assays, trapidil at therapeutic concentrations causes selective phosphorylation of cellular proteins through positive modulation of regulatory subunit RII(α/β) containing protein kinase A (PKA).[3][4] At higher, non-physiologically relevant concentrations, which are generally not achieved after administration of therapeutic doses, non-selective inhibition of phosphodiesterases occurs.[4] Further, the previous documented activities as an antagonist of platelet-derived growth factor[5] are abolished when a PKA inhibitor is administered, suggesting that these noted activities are PKA mediated.[4] At these higher concentrations,[6] additional effects have been noted including vasodilation and inhibition of platelet aggregation[7][8]
